Antibiotic resistance (AR), when germs do not respond to the drugs designed to kill them, threatens to return us to the time when simple infections were often fatal. CDC is committed to protecting people and the future of the healthcare, veterinary, and agriculture industries from the threat of antibiotic resistance.

The AR Investment Map showcases CDC’s critical activities in the U.S. and abroad to combat AR with investments in laboratory and epidemiological expertise and public health innovation. The map also includes CDC’s COVID-19 efforts related to combating AR, highlighted in a new fact sheet.

CDC supports most of these activities through its AR Solutions Initiative, while also leveraging investments from successful programs across the agency for maximum efficiency.

**DETECTION, RESPONSE & CONTAINMENT**

- **Laboratory & Diagnostics:** Gold-standard lab capacity offered to all state and regional labs through CDC’s AR Laboratory Network
- **Epidemiology Capacity for Response:** Increased capacity in state and local health departments for rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread

**PREVENTION**

- **Surveillance & Science:** More effective prevention of healthcare-associated infections, foodborne illness, and gonorrhea
- **Improved Antibiotic Use:** With partners, improve antibiotic use to ensure antibiotics work to protect patients from life-threatening infections or sepsis

**INNOVATION**

- **Insights for Practice:** With academic and healthcare partners, CDC is investing in innovations and collaborating with investigators to identify and implement new ways to prevent antibiotic-resistant infections and their spread
- **Research and Development:** Sharing isolates that inform development of new drugs and diagnostics, and making public CDC’s sequencing data from AR pathogens to spur innovation in industry

These investments work toward meeting national goals to prevent drug-resistant infections as outlined in the [National Action Plan for Combating Antibiotic-Resistant Bacteria](https://www.cdc.gov/drugresistance/about/index.html).

See CDC’s AR investments by state at [ARinvestments.cdc.gov](https://www.arinvestments.cdc.gov).